Environmental factors as modulators of neurodegeneration: Insights from gene-environment interactions in Huntington's disease

Neuroscience and Biobehavioral Reviews

Volumn 52, Issue , 2015, Pages 178-192

  Mo, Christina ^a,b   Hannan, Anthony J ^a   Renoir, Thibault ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alzheimer's disease; Cognitive stimulation; Diet; Environmental enrichment; Environmental modifiers; Exercise; Lifestyle; Neurodegenerative disorder; Parkinson's disease; Physical activity; Polyglutamine disease; Stress; Tandem repeat disorders

Indexed keywords

ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; OMEGA 3 FATTY ACID; POLYPHENOL; UBIDECARENONE; URIC ACID;

AGING; ALZHEIMER DISEASE; ANXIETY; BDNF GENE; BEVERAGE; CALORIC RESTRICTION; CEREBROVASCULAR ACCIDENT; CHRONIC STRESS; COGNITIVE STIMULATION; COHORT ANALYSIS; CROSS FERTILIZATION; DIET SUPPLEMENTATION; DISEASE COURSE; ENDOPHENOTYPE; ENVIRONMENTAL FACTOR; EPILEPSY; EXERCISE; FORCED SWIM TEST; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GENOTYPE ENVIRONMENT INTERACTION; HIPPOCAMPUS; HOPELESSNESS; HUMAN; HUNTINGTON CHOREA; MEDITERRANEAN DIET; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENSORIMOTOR FUNCTION; SEX DIFFERENCE; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; STIMULATION; ANIMAL; COMPLICATION; DEGENERATIVE DISEASE; DISEASE MODEL; ENVIRONMENT; GENETICS; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; HUMANS; HUNTINGTON DISEASE; MICE; NEURODEGENERATIVE DISEASES;

EID: 84925244472     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.03.003     Document Type: Review

References (251)

1. Adlard P.A., Perreau V.M., Pop V., Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:4217-4221.
2. Alcalay R.N., Gu Y., Mejia-Santana H., Cote L., Marder K.S., Scarmeas N. The association between Mediterranean diet adherence and Parkinson's disease. Mov. Disord. 2012, 27:771-774.
3. Altschuler E.L. Strenuous, intensive, long-term exercise does not prevent or delay the onset of Huntington's disease. Med. Hypotheses 2006, 67:1429-1430.
4. Anca M.H., Gazit E., Loewenthal R., Ostrovsky O., Frydman M., Giladi N. Different phenotypic expression in monozygotic twins with Huntington disease. Am. J. Med. Genet. A 2004, 124A:89-91.
5. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., et al. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
6. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4:398-403.
7. Armstrong M.J., Miyasaki J.M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012, 79:597-603.
8. Arning L., Epplen J.T. Genetic modifiers of Huntington's disease: beyond CAG. Future Neurol. 2011, 7:93-109.
9. Ascherio A., Zhang S.M., Hernán M.A., Kawachi I., Colditz G.A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50:56-63.
10. Auinger P., Kieburtz K., McDermott M.P. The relationship between uric acid levels and Huntington's disease progression. Mov. Disord. 2010, 25:224-228.
11. Aungier J., Cuesta M., Morton A. Voluntary exercise improves circadian function in a mouse model of Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2012, 83:A14.
12. Aylward E.H., Harrington D.L., Mills J.A., Nopoulos P.C., Ross C.A., et al. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J. Huntingtons Dis. 2013, 2:477-489.
13. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
14. Aziz N.A., Anguelova G.V., Marinus J., Lammers G.J., Roos R.A.C. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat. Disord. 2010, 16:345-350.
15. Aziz N.A., Pijl H., Frolich M., van der Graaf A.W.M., Roelfsema F., Roos R.A.C. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab. 2009, 94:1223-1228.
16. Babenko O., Kovalchuk I., Metz G.A. Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res. 2012, 1444:96-111.
17. Bates G., Harper P., Jones L. Huntington's Disease 2002, Oxford University Press, New York.
18. Beal M.F., Shults C.W. Effects of coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 2003, 18:153-161.
19. Benn C.L.P., Luthi-Carter R.P., Kuhn A.P., Sadri-Vakili G.P., Blankson K.L., et al. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger rna expression in a mouse model of Huntington disease. J. Neuropathol. Exp. Neurol. 2010, 69:817-827.
20. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Mendes de Leon C.F., et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003, 60:1909-1915.
21. Bird T.D., Omenn G.S. Monozygotic twins with Huntington's disease in a family expressing the rigid variant. Neurology 1975, 25:1126.
22. Bjorkqvist M., Petersen A., Bacos K., Isaacs J., Norlen P., et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1713-1721.
23. Blackstone C. Huntington's disease: from disease mechanisms to therapies. Drug Discov. Today 2014, 19:949-950.
24. Bode F.J., Stephan M., Suhling H., Pabst R., Straub R.H., et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17{beta}-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum. Mol. Genet. 2008, 17:2595-2609.
25. Bombard Y., Palin J., Friedman J.M., Veenstra G., Creighton S., et al. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2012, 159B:217-226.
26. Borghjid S., Feinman R.D. Response of C57Bl/6 mice to a carbohydrate-free diet. Nutr. Metab. 2012, 9:69.
27. Bosma H., Van Boxtel M.P.J., Ponds R.W.H.M., Houx P.J., Burdorf A., Jolles J. Mental work demands protect against cognitive impairment: MAAS prospective cohort study. Exp. Aging Res. 2003, 29:33-45.
28. Brooks S.P., Higgs G., Janghra N., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice. Brain Res. Bull. 2012, 88:113-120.
29. Brooks S.P., Janghra N., Workman V.L., Bayram-Weston Z., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res. Bull. 2012, 88:94-103.
30. Brotherton A., Campos L., Rowell A., Zoia V., Simpson S.A. Nutritional management of individuals with Huntington's disease: EHDN standards of care nutritional guidelines,. J. Neurol. Neurosurg. Psychiatry 2010, 81:A41.
31. Brown B.M., Peiffer J.J., Martins R.N. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?. Mol. Psychiatry 2013, 18:864-874.
32. Brown R.C., Lockwood A.H., Sonawane B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 2005, 113:1250-1256.
33. Browne S.E., Bowling A.C., Macgarvey U., Baik M.J., Berger S.C., et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
34. Buruma O.J.S., Van der Kamp W., Barendswaard E.C., Roos R.A.C., Kromhout D., Van der Velde E.A. Which factors influence age at onset and rate of progression in Huntington's disease?. J. Neurol. Sci. 1987, 80:299-306.
35. Busse M., Quinn L., Debono K., Jones K., Collett J., et al. A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease. J. Neurol. Phys. Therapy 2013, 37:149-158.
36. Carroll J.C., Iba M., Bangasser D.A., Valentino R.J., James M.J., et al. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J. Neurosci. 2011, 31:14436-14449.
37. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 2000, 15:925-937.
38. Cepeda C., Cummings D., Hickey M., Kleiman-Weiner M., Chen J., et al. Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington's disease: exercise, adenosine receptors and ampakines. PLoS Curr. 2010, 2.
39. Cha J.H.J., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. B: Biol. Sci. 1999, 354:981-989.
40. Chandra A., Johri A., Beal M.F. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov. Disord. 2014, 29:285-293.
41. Choi H.K., Liu S., Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 52:283-289.
42. Chou S.-Y., Lee Y.-C., Chen H.-M., Chiang M.-C., Lai H.-L., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005, 93:310-320.
43. Clabough E.B.D. Huntington's disease: the past, present, and future search for disease modifiers. Yale J. Biol. Med. 2013, 86:217-233.
44. Clifford J.J., Drago J., Natoli A.L., Wong J.Y.F., Kinsella A., et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002, 109:81-88.
45. Cotman C.W., Berchtold N.C., Christie L.-A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007, 30:464-472.
46. Craggs L., Kalaria R.N. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport 2011, 22:1-3.
47. Cuesta M., Aungier J., Morton A.J. Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2013, 63:85-91.
48. Dijk J.G., Velde E.A., Roos R.A.C., Bruyn G.W. Juvenile Huntington disease. Hum. Genet. 1986, 73:235-239.
49. Djamshidian A., Lees A.J. Can stress trigger Parkinson's disease?. J. Neurol. Neurosurg. Psychiatry 2014, 85:878-881.
50. Djoussé L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59:1325-1330.
51. Döbrössy M.D., Busse M., Piroth T., Rosser A., Dunnett S., Nikkhah G. Review: neurorehabilitation with neural transplantation. Neurorehabil. Neural Repair 2010, 24:692-701.
52. Döbrössy M.D., Dunnett S.B. Environmental housing and duration of exposure affect striatal graft morphology in a rodent model of Huntington's disease. Cell Transplant. 2008, 17:1125-1134.
53. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., et al. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 2007, 28:197-205.
54. Dorner J.L., Miller B.R., Barton S.J., Brock T.J., Rebec G.V. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav. Brain Res. 2007, 178:90-97.
55. Downing N., Smith M., Beglinger L., Mills J., Duff K., et al. Perceived stress in prodromal Huntington disease. Psychol. Health 2012, 27:196-209.
56. Du X., Leang L., Mustafa T., Renoir T., Pang T.Y., Hannan A.J. Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease. Transl. Psychiatry 2012, 2:e133.
57. Du X., Pang T.Y., Mo C., Renoir T., Wright D.J., Hannan A.J. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease. Exp. Neurol. 2015, 263:63-71.
58. Duan W., Guo Z., Jiang H., Ware M., Li X., Mattson M. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100.
59. Duan W., Guo Z., Mattson M.P. Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. J. Neurochem. 2001, 76:619-626.
60. Dubreucq S., Marsicano G., Chaouloff F. Emotional consequences of wheel running in mice: which is the appropriate control?. Hippocampus 2011, 21:239-242.
61. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 1993, 4:387-392.
62. Ehrnhoefer D.E., Butland S.L., Pouladi M.A., Hayden M.R. Mouse models of Huntington disease: variations on a theme. Dis. Model Mech. 2009, 2:123-129.
63. Esposito E., Rotilio D., Di Matteo V., Di Giulio C., Cacchio M., Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol. Aging 2002, 23:719-735.
64. Feder A., Nestler E.J., Charney D.S. Psychobiology and molecular genetics of resilience. Nat. Rev. Neurosci. 2009, 10:446-457.
65. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 1996, 11:321-323.
66. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
67. Foroud T., Gray J., Ivashina J., Conneally P.M. Differences in duration of Huntington's disease based on age at onset. J. Neurol. Neurosurg. Psychiatry 1999, 66:52-56.
68. Fratiglioni L., Paillard-Borg S., Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004, 3:343-353.
69. Friedman J.H., Trieschmann M.E., Myers R.H., et al. Monozygotic Twins Discordant for Huntington Disease After 7 Years 2005, American Medical Association, Chicago, IL, USA, 3 pp.
70. Gapp K., Woldemichael B.T., Bohacek J., Mansuy I.M. Epigenetic regulation in neurodevelopment and neurodegenerative diseases. Neuroscience 2014, 264:99-111.
71. Gargiulo M., Lejeune S., Tanguy M.L., Lahlou-Laforêt K., Faudet A., et al. Long-term outcome of presymptomatic testing in Huntington disease. Eur. J. Hum. Genet. 2009, 17:165-171.
72. Georgiou N., Bradshaw J.L., Chiu E., Tudor A., O'Gorman L., Phillips J.G. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov. Disord. 1999, 14:320-325.
73. Gil-Mohapel J.S., Brocardo P.R., Christie B. The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?. Curr. Drug Targets 2014, 15:454-468.
74. Glass M., van Dellen A., Blakemore C., Hannan A.J., Faull R.L.M. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212.
75. Godinho B.M., Malhotra M., O'Driscoll C.M., Cryan J.F. Delivering a disease-modifying treatment for Huntington's disease. Drug Discov. Today 2015, 20:50-64.
76. Goodman A.O.G., Murgatroyd P.R., Medina-Gomez G., Wood N.I., Finer N., et al. The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp. Neurol. 2008, 210:691-698.
77. Goodwin V.A., Richards S.H., Taylor R.S., Taylor A.H., Campbell J.L. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 2008, 23:631-640.
78. Gourley S.L., Swanson A.M., Koleske A.J. Corticosteroid-induced neural remodeling predicts behavioral vulnerability and resilience. J. Neurosci. 2013, 33:3107-3112.
79. Guo Z., Rudow G., Pletnikova O., Codispoti K.-E., Orr B.A., et al. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov. Disord. 2012, 27:1379-1386.
80. Gurpegui M., Jurado D., Luna J.D., Fernández-Molina C., Moreno-Abril O., Gálvez R. Personality traits associated with caffeine intake and smoking. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:997-1005.
81. Gusella J.F., MacDonald M.E. Huntington's disease. Semin. Cell Biol. 1995, 6:21-28.
82. Gusella J.F., MacDonald M.E. Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem. Sci. 2006, 31:533-540.
83. Halagappa V.K.M., Guo Z., Pearson M., Matsuoka Y., Cutler R.G., et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2007, 26:212-220.
84. Hamer M., Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol. Med. 2009, 39:3-11.
85. Hannan A.J. Huntington's disease: which drugs might help patients?. IDrugs 2004, 7:351-358.
86. Harrison D.J., Busse M., Openshaw R., Rosser A.E., Dunnett S.B., Brooks S.P. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model. Exp. Neurol. 2013, 248:457-469.
87. Heemskerk A.W., Roos R.A. Aspiration pneumonia and death in Huntington's disease. PLoS Curr. 2012, 4:RRN1293.
88. Hersch S.M., Rosas H.D. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008, 5:226-236.
89. Hickey M.A., Zhu C., Medvedeva V., Franich N.R., Levine M.S., Chesselet M.-F. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol. Cell. Neurosci. 2012, 49:149-157.
90. Ho D.J., Calingasan N.Y., Wille E., Dumont M., Beal M.F. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol. 2010, 225:74-84.
91. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
92. Huang N.-K., Lin J.-H., Lin J.-T., Lin C.-I., Liu E.M., et al. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS ONE 2011, 6:e20934.
93. Hultsch D.F., Hertzog C., Small B.J., Dixon R.A. Use it or lose it: engaged lifestyle as a buffer of cognitive decline in aging?. Psychol. Aging 1999, 14:245-263.
94. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
95. Huntington Study Group Trend-HD Investigators Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the trend-HD study. Arch. Neurol. 2008, 65:1582-1589.
96. Imarisio S., Carmichael J., Korolchuk V., Chen C.-W., Saiki S., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J 2008, 412:191-209.
97. Iraola-Guzmán S., Estivill X., Rabionet R. DNA methylation in neurodegenerative disorders: a missing link between genome and environment?. Clin. Genet. 2011, 80:1-14.
98. Jeong Y.H., Park C.H., Yoo J., Shin K.Y., Ahn S.-M., et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006, 20:729-731.
99. Jicha G.A., Swaminathan A. Nutrition and prevention of Alzheimer's dementia. Front. Aging Neurosci. 2014, 6.
100. Joseph J., Cole G., Head E., Ingram D. Nutrition, brain aging, and neurodegeneration. J. Neurosci. 2009, 29:12795-12801.
101. Kalmijn S., Feskens E.J.M., Launer L.J., Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am. J. Epidemiol. 1997, 145:33-41.
102. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993, 43:13-20.
103. Kemppainen N.M., Aalto S., Karrasch M., Någren K., Savisto N., et al. Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann. Neurol. 2008, 63:112-118.
104. Khalil H., Quinn L., van Deursen R., Dawes H., Playle R., et al. What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study. Clin. Rehabil. 2013, 27:646-658.
105. Kibel A., Drenjancevic-Peric I. Impact of glucocorticoids and chronic stress on progression of Parkinson's disease. Med. Hypotheses 2008, 71:952-956.
106. Kieburtz K., Wunderle K.B. Parkinson's disease: evidence for environmental risk factors. Mov. Disord. 2013, 28:8-13.
107. Kloos A.D., Fritz N.E., Kostyk S.K., Young G.S., Kegelmeyer D.A. Video game play (Dance Dance Revolution) as a potential exercise therapy in Huntington's disease: a controlled clinical trial. Clin. Rehabil. 2013, 27:972-982.
108. Kohl Z., Kandasamy M., Winner B., Aigner R., Gross C., et al. Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Brain Res. 2007, 2:11554-11633.
109. Koroshetz W.J., Jenkins B.G., Rosen B.R., Flint Beal M. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41:160-165.
110. Kosinski C.M., Schlangen C., Gellerich F.N., Gizatullina Z., Deschauer M., et al. Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov. Disord. 2007, 22:1637-1640.
111. Kovtun I.V., Therneau T.M., McMurray C.T. Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. Hum. Mol. Genet. 2000, 9:2767-2775.
112. Landles C., Bates G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 2004, 5:958-963.
113. Langbehn D., Brinkman R., Falush D., Paulsen J., Hayden M. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65:267-277. On behalf of an International Huntington's Disease Collaborative Group.
114. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., French-Constant C., et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt 7):1329-1341.
115. Lazic S.E., Goodman A.O.G., Grote H.E., Blakemore C., Morton A.J., et al. Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res. 2007, 1151:219-226.
116. Lazic S.E., Grote H.E., Blakemore C., Hannan A.J., van Dellen A., et al. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 2006, 23:1829-1838.
117. Lee J., Seroogy K.B., Mattson M.P. Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J. Neurochem. 2002, 80:539-547.
118. Lee J.M., Ramos E.M., Macdonald M., Gusella J. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012, 78.
119. Leeflang E.P., Zhang L., Tavare S., Hubert R., Srinidhi J., et al. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum. Mol. Genet. 1995, 4:1519-1526.
120. Li J.-Y., Conforti L. Axonopathy in Huntington's disease. Exp. Neurol. 2013, 246:62-71.
121. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
122. Lista I., Sorrentino G. Biological mechanisms of physical activity in preventing cognitive decline. Cell. Mol. Neurobiol. 2010, 30:493-503.
123. Logge W., Kingham J., Karl T. Behavioural consequences of IVC cages on male and female C57BL/6J mice. Neuroscience 2013, 237:285-293.
124. López-Sendón J.L., Royuela A., Trigo P., Orth M., Lange H., et al. What is the impact of education on Huntington's disease?. Mov. Disord. 2011, 26:1489-1495.
125. Luchsinger J.A., Tang M., Shea S., Mayeux R. CAloric intake and the risk of alzheimer disease. Arch. Neurol. 2002, 59:1258-1263.
126. Luchtman D.W., Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 2013, 64:550-565.
127. MacDonald M., Barnes G., Srinidhi J., Duyao M., Ambrose C., et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 1993, 30:982-986.
128. Machado A., Herrera Antonio J., de Pablos Rocío M., Espinosa-Oliva Ana M., Sarmiento M., et al. Chronic stress as a risk factor for Alzheimer's disease. Rev. Neurosci. 2014, 785.
129. Maher P., Dargusch R., Bodai L., Gerard P.E., Purcell J.M., Lawrence Marsh J. Erk activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. 2011, 20:261-270.
130. Maia L., De Mendonça A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 2002, 9:377-382.
131. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., et al. Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
132. Marder K., Gu Y., Eberly S., et al. Relationship of mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013, 70:1382-1388.
133. Marder K., Zhao H., Eberly S., Tanner C.M., Oakes D., et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 2009, 73:385-392.
134. Martin B., Ji S., Maudsley S., Mattson M.P. Control laboratory rodents are metabolically morbid: why it matters. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6127-6133.
135. Mattson M.P., Chan S.L., Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 2002, 637-672.
136. Mattson M.P., Duan W., Lee J., Guo Z. Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment: molecular mechanisms. Mech. Ageing Dev. 2001, 122:757-778.
137. Mazarakis N., Mo C., Renoir T., van Dellen A., Deacon R., et al. 'Super-enrichment' reveals dose-dependent therapeutic effects of environmental stimulation in a transgenic mouse model of Huntington's disease. J. Huntingtons Dis. 2014, 3:299.
138. McLear J.A., Lebrecht D., Messer A., Wolfgang W.J. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J. 2008, 22:2003-2011.
139. McOmish C.E., Hannan A.J. Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opin. Ther. Targets 2007, 11:899-913.
140. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst. Rev. 2009, CD006455.
141. Migliore L., Coppedè F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 2009, 667:82-97.
142. Mitra R., Ferguson D., Sapolsky R.M. Mineralocorticoid receptor overexpression in basolateral amygdala reduces corticosterone secretion and anxiety. Biol. Psychiatry 2009, 66:686-690.
143. Mo C., Pang T.Y., Ransome M.I., Hill R.A., Renoir T., Hannan A.J. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice. Neurobiol. Dis. 2014, 69:248-262.
144. Mo C., Renoir T., Hannan A.J. Novel ethological endophenotypes in a transgenic mouse model of Huntington's disease. Behav. Brain Res. 2014, 276:17-27.
145. Mo C., Renoir T., Hannan A.J. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice. Neurobiol. Dis. 2014, 71:81-94.
146. Mo C., Renoir T., Hannan A.J. Ethological endophenotypes are altered by elevated stress hormone levels in both Huntington's disease and wildtype mice. Behav. Brain Res. 2014, 274:118-127.
147. Mo C., Renoir T., Pang T.Y.C., Hannan A.J. Short-term memory acquisition in female Huntington's disease mice is vulnerable to acute stress. Behav. Brain Res. 2013, 253:318-322.
148. Moore M., DeLorenzo M., Yan L., Chirieac D., Bravo C.A., et al. Chronic caloric restriction improves locomotor activity in aging female mice. FASEB J. 2011, 25.
149. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L.M., et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
150. Myers R.H. Huntington's disease genetics. NeuroRX 2004, 1:255-262.
151. Nance M., Myers R.H. Juvenile onset Huntington's disease - clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:153-157.
152. Newberry R.C. Environmental enrichment: increasing the biological relevance of captive environments. Appl. Anim. Behav. Sci. 1995, 44:229-243.
153. Ng C.W., Yildirim F., Yap Y.S., Dalin S., Matthews B.J., et al. Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2354-2359.
154. Ngandu T., Von Strauss E., Helkala E.L., Winblad B., Nissinen A., et al. Education and dementia: what lies behind the association?. Neurology 2007, 69:1442-1450.
155. Nithianantharajah J., Barkus C., Murphy M., Hannan A.J. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 2008, 29:490-504.
156. Nithianantharajah J., Hannan A.J. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat. Rev. Neurosci. 2006, 7:697-709.
157. Nithianantharajah J., Hannan A.J. The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog. Neurobiol. 2009, 89:369-382.
158. Nithianantharajah J., Hannan A.J. Mechanisms mediating brain and cognitive reserve: experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:331-339.
159. Oepen H. Discordant features of monozygotic twin sisters with Huntington's chorea. Adv. Neurol. 1973, 1:199-201.
160. Orvoen S., Pla P., Gardier A.M., Saudou F., David D.J. Huntington's disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation. Neurosci. Lett. 2012, 507:127-132.
161. Owen A.M., Hampshire A., Grahn J.A., Stenton R., Dajani S., et al. Putting brain training to the test. Nature 2010, 465:775-778.
162. Pacák K., Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr. Rev. 2001, 22:502-548.
163. Pang T.Y.C., Du X., Zajac M.S., Howard M.L., Hannan A.J. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2009, 18:753-766.
164. Pang T.Y.C., Hannan A.J. Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity. Neuropharmacology 2013, 64:515-528.
165. Pang T.Y.C., Stam N.C., Nithianantharajah J., Howard M.L., Hannan A.J. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington's disease transgenic mice. Neuroscience 2006, 141:569-584.
166. Pardon M.-C., Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders?. Neurosci. Biobehav. Rev. 2008, 32:1103-1120.
167. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005, 37:349-350.
168. Pasinetti G.M., Wang J., Marambaud P., Ferruzzi M., Gregor P., et al. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 2011, 232:1-6.
169. Paul B.D., Sbodio J.I., Xu R., Vandiver M.S., Cha J.Y., et al. Cystathionine [ggr]-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 2014, 509:96-100.
170. Peavy G.M., Jacobson M.W., Salmon D.P., Gamst A.C., Patterson T.L., et al. The influence of chronic stress on dementia-related diagnostic change in older adults. Alzheimer Dis. Assoc. Disord. 2012, 26:260-266.
171. Pietropaolo S., Delage P., Cayzac S., Crusio W.E., Cho Y.H. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice. PLoS ONE 2011, 6:e19965.
172. Pla P., Orvoen S., Saudou F., DAVID D.J., Humbert S. Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms. Front. Behav. Neurosci. 2014, 8.
173. Polleri A., Savoldi F., Muratorio A., Masturzo P., Murialdo G., et al. Circadian rhythmicity of prolactin secretion in Huntington's chorea. Life Sci. 1980, 26:1609-1617.
174. Potter M.C., Yuan C., Ottenritter C., Mughal M., van Praag H. Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's disease. PLoS Curr. 2010, 2:RRN1201.
175. Pouladi M.A., Morton A.J., Hayden M.R. Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci. 2013, 14:708-721.
176. Puri B., Bydder G., Manku M., Clarke A., Waldman A., Beckmann C. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J. Int. Med. Res. 2008, 36:896-905.
177. Puri B.K., Bydder G.M., Counsell S.J., Corridan B.J., Richardson A.J., et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002, 13:123-126.
178. Puri B.K., Leavitt B.R., Hayden M.R., Ross C.A., Rosenblatt A., et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286-292.
179. Radecki D.T., Brown L.M., Martinez J., Teyler T.J. BDNF protects against stress-induced impairments in spatial learning and memory and LTP. Hippocampus 2005, 15:246-253.
180. Ransome M.I., Hannan A.J. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice. Mol. Cell. Neurosci. 2013, 54:93-107.
181. Rebec G.V., Barton S.J., Marseilles A.M., Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 2003, 14:1263-1265.
182. Rebec G.V., Conroy S.K., Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137:327-336.
183. Renoir T., Chevarin C., Lanfumey-Mongredien L., Hannan A. Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice. PLoS Curr. 2011, 3:RRN1281.
184. Renoir T., Pang T.Y.C., Mo C., Chan G., Chevarin C., et al. Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice. J. Physiol. 2013, 591:41-55.
185. Renoir T., Pang T.Y.C., Zajac M.S., Chan G., Du X., et al. Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. Br. J. Pharmacol. 2012, 165:1375-1389.
186. Renoir T., Zajac M.S., Du X., Pang T.Y., Leang L., et al. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PLoS ONE 2011, 6:e22133.
187. Roos R.A., Vegter-van der Vlis M., Hermans J., Elshove H.M., Moll A.C., et al. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J. Med. Genet. 1991, 28:515-519.
188. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
189. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283:2674-2679.
190. Rothman S.M., Herdener N., Camandola S., Texel S.J., Mughal M.R., et al. 3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol. Aging 2012, 33:830.e1-830.e12.
191. Samieri C., Sun Q., Townsend M.K., Chiuve S.E., Okereke O.I., et al. The association between dietary patterns at midlife and health in agingan observational study. Ann. Intern. Med. 2013, 159:584-591.
192. Sapolsky R., Uno H., Rebert C., Finch C. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J. Neurosci. 1990, 10:2897-2902.
193. Sassone J., Colciago C., Cislaghi G., Silani V., Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 2009, 219:385-397.
194. Scarmeas N., Levy G., Tang M.-X., Manly J., Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 2001, 57:2236-2242.
195. Scarmeas N., Stern Y., Tang M.-X., Mayeux R., Luchsinger J.A. Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 2006, 59:912-921.
196. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 315:149-153.
197. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp. Neurol. 2004, 187:137-149.
198. Schulte P.A., Burnett C.A., Boeniger M.F., Johnson J. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am. J. Public Health 1996, 86:1281-1288.
199. Shannon K.M. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis. Handbook of Clinical Neurology 2011, 3-13. Elsevier, (Chapter 1). J.W. William, T. Eduardo (Eds.).
200. Simonin C., Duru C., Salleron J., Hincker P., Charles P., et al. Association between caffeine intake and age at onset in Huntington's disease. Neurobiol. Dis. 2013, 58:179-182.
201. Smith K.M., Matson S., Matson W.R., Cormier K., Del Signore S.J., et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:616-626.
202. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 1993, 4:393-397.
203. Sotiropoulos I., Catania C., Pinto L.G., Silva R., Pollerberg G.E., et al. Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J. Neurosci. 2011, 31:7840-7847.
204. Sparbel K.J.H., Driessnack M., Williams J.K., Schutte D.L., Tripp-Reimer T., et al. Experiences of teens living in the shadow of Huntington disease. J. Genet. Couns. 2008, 17:327-335.
205. Spargo E., Everall I.P., Lantos P.L. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry 1993, 56:487-491.
206. Spindler M., Flint Beal M., Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr. Dis. Treat. 2009, 5:597-610.
207. Spires T.L., Grote H.E., Garry S., Cordery P.M., Van Dellen A., et al. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 2004, 19:2799-2807.
208. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 2004, 24:2270-2276.
209. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Compar. Neurol. 2005, 490::354-370.
210. Stern Y. The concept of cognitive reserve: a catalyst for research. J. Clin. Exp. Neuropsychol. 2003, 25:589-593.
211. Stine O.C., Pleasant N., Franz M.L., Abbott M.H., Folstein S.E., Ross C.A. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum. Mol. Genet. 1993, 2:1547-1549.
212. Sudarsky L., Myers R.H., Walshe T.M. Huntington's disease in monozygotic twins reared apart. J. Med. Genet. 1983, 20:408-411.
213. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
214. Sullivan F.R., Bird E.D., Alpay M., Cha J.H. Remotivation therapy and Huntington's disease. J. Neurosci. Nurs. 2001, 33:136-142.
215. Swami M., Hendricks A.E., Gillis T., Massood T., Mysore J., et al. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Genet. 2009, 18:3039-3047.
216. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 2006, 23:44-53.
217. Tasset I., Pontes A.J., Hinojosa A.J., de la Torre R., Túnez I. Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model. Nutr. Neurosci. 2011, 14:106-111.
218. Tebbenkamp A.T.N., Swing D., Tessarollo L., Borchelt D.R. Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment. Hum. Mol. Genet. 2011, 20:1633-1642.
219. The Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
220. Timman R., Roos R., Maat-Kievit A., Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol. 2004, 23:189-197.
221. Tortosa-Martínez J., Clow A. Does physical activity reduce risk for Alzheimer's disease through interaction with the stress neuroendocrine system?. Stress 2012, 15:243-261.
222. Trejo A., Boll M.-C., Alonso M.E., Ochoa A., Velásquez L. Use of oral nutritional supplements in patients with Huntington's disease. Nutrition 2005, 21:889-894.
223. Trembath K., Horton Z., Tippett L., Hogg V., Collins V., et al. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov. Disord. 2010, 58:179-182.
224. Vaddadi K.S., Soosai E., Chui E., Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002, 13:29-33.
225. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
226. van Dellen A., Cordery P., Spires T., Blakemore C., Hannan A.J. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci. 2008, 9:34.
227. van der Burg J.M.M., Björkqvist M., Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009, 8:765-774.
228. van der Staay F.J. Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res. Rev. 2006, 52:131-159.
229. van Duijn E., Craufurd D., Hubers A.A.M., Giltay E.J., Bonelli R., et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J. Neurol. Neurosurg. Psychiatry 2014, 85:1411-1418.
230. van Praag H. Neurogenesis and exercise: past and future directions. Neuromolecular Med. 2008, 10:128-140.
231. van Praag H., Kempermann G., Gage F.H. Neural consequences of environmental enrichment. Nat. Rev. Neurosci. 2000, 1:191-198.
232. Van Raamsdonk J.M., Murphy Z., Selva D.M., Hamidizadeh R., Pearson J., et al. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
233. Van Raamsdonk J.M., Pearson J., Rogers D.A., Lu G., Barakauskas V.E., et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol. 2005, 196:266-272.
234. Vassos E., Panas M., Kladi A., Vassilopoulos D. Effect of CAG repeat length on psychiatric disorders in Huntington's disease. J. Psychiatr. Res. 2008, 42:544-549.
235. Wang J., Pfleger C.M., Friedman L., Vittorino R., Zhao W., et al. Potential application of grape derived polyphenols in Huntington's disease. Transl. Neurosci. 2010, 1:95-100.
236. Watanabe Y., Gould E., McEwen B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992, 588:341-345.
237. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3498-3503.
238. Williams J.K., Skirton H., Paulsen J.S., Tripp-Reimer T., Jarmon L., et al. The emotional experiences of family carers in Huntington disease. J. Adv. Nurs. 2009, 65:789-798.
239. Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog. Neuropsychopharmacol. Biol. Psychiatry 1986, 10:677-690.
240. Wilson R.S., Bennett D.A., Bienias J.L., Aggarwal N.T., Mendes de Leon C.F., et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002, 59:1910-1914.
241. Wood N.I., Carta V., Milde S., Skillings E.A., McAllister C.J., et al. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS ONE 2010, 5:e9077.
242. Wood N.I., Glynn D., Morton A.J. Brain training improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2011, 42:427-437.
243. Woolley C.S., Gould E., Frankfurt M., McEwen B.S. Naturally occurring fluctuations in dendritic spine density on adult hippocampal pyramidal neurons. J. Neurosci. 1990, 10.
244. Wright D.J., Renoir T., Smith Z.M., Frazier A.E., Francis P.S., et al. N-Acetylcysteine improves mitochondrial function and ameliorates behavioural deficits in the R6/1 mouse model of Huntington's disease. Transl. Psychiatry 2015, 5:e492.
245. Würbel H. Ideal homes? Housing effects on rodent brain and behaviour. Trends Neurosci. 2001, 24:207-211.
246. Yang W., Gray M. Mouse models for validating preclinical candidates for Huntington's disease. Neurobiology of Huntington's Disease 2010, 165-195. CRC Press.
247. Zajac M.S., Pang T.Y.C., Wong N., Weinrich B., Leang L.S.K., et al. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 2010, 20:621-636.
248. Zappacosta B., Monza D., Meoni C., et al. PSychiatric symptoms do not correlate with cognitive decline, motor symptoms, or cag repeat length in Huntington's disease. Arch. Neurol. 1996, 53:493-497.
249. Zielonka D., Marinus J., Roos R.A.C., De Michele G., Di Donato S., et al. The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism Relat. Disord. 2013, 19:192-197.
250. Zinzi P., Salmaso D., De Grandis R., Graziani G., Maceroni S., et al. Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study. Clin. Rehabil. 2007, 21:603-613.
251. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.